Canadian Thalidomide Survivors Support Program

Important Updates

 

 

CTSSP Application Deadline:

Step 1 – Preliminary Screening Applications are now available for any living individual who believes that they are a Thalidomide Survivor, including those previously denied under the 1991 EAP or the 2015 TSCP. Click here to download the form or call 1-877-507-7706 (TTY: 1-877-627-7027) to have one sent to you. The CTSSP Application deadline is postmarked by June 3, 2024 to the Administrator.

 

Confirmed Survivor Survey:

A summary of the results of the Survey may be found here. The next Survey will be distributed in February of 2020.

 

Reassessment:

Confirmed Survivors who are currently at a level 1 or a level 2, may request reassessment of their health status for the 2019-2020 FY anytime between April 1, 2019 and March 31, 2020. Click here to download the application.

 

EMAF:

EMAF applications are now being accepted for the 2019-2020 FY. Confirmed Survivors may submit up to a maximum of two applications per year anytime between April 1, 2019 and March 31, 2020. Click here to download the application.

 

You may also call the Administrator at 1-877-507-7706 (TTY: 1-877-627-7027) or by email to info@tsspcanada.ca to have any of the forms sent to you by mail or email.

The CTSSP Assessment Application Process

 

Any living individual who believes that they are a Thalidomide Survivor, including those previously denied under the 1991 EAP or the 2015 TSCP, must submit a Step 1 - Preliminary Screening Application for assessment to the Administrator prior to the application deadline of June 3, 2024 and must proceed successfully through all the three steps below to be eligible for support under the Canadian Thalidomide Survivors Support Program (“CTSSP”).

 

Step 1: Preliminary Screening:

 

At Step 1, you must submit a Step 1 - Preliminary Screening Application postmarked by June 3, 2024.

 

To be eligible under the CTSSP:

 

  1. You must have been born in Canada between December 3, 1957 and December 21, 1967;

  2. Your date of birth must coincide with maternal ingestion of Thalidomide in the first trimester of pregnancy; and

  3. The nature of your congenital malformations must be consistent with known characteristics of congenital malformations linked to Thalidomide.
  •  
  • The CTSSP will consider individuals whose mothers may have accessed Thalidomide prior to its authorized use in Canada. Eligibility will be based on the earliest global market availability in West Germany (October 1, 1957) and up to five years after its withdrawal from the Canadian Market (March 2, 1962). December 3, 1957 is the earliest date of birth allowing for a premature birth at 22 weeks of gestation and assumes maternal ingestion of the drug on October 1, 1957, the last day of the first trimester. December 21, 1967 allows for a five year grace period following removal of Thalidomide from the Canadian Market on March 2, 1962 and assumes post-term delivery at 42 weeks.

 

Individuals who meet the Step 1 eligibility requirements will advance to Step 2

 

Step 2: Probability Assessment:

 

At Step 2, you will be required to submit a detailed application form. Your physician will need to complete the Step 2 - Probability Assessment Application for you as the Step 2 - Probability Assessment Application requires detailed medical responses to specific questions about your Thalidomide related injuries. Once the completed application is received, it will be reviewed carefully by the Administrator. The information provided at this step will be input into a diagnostic algorithm for Thalidomide embryopathy by qualified medical staff. The algorithm will harness the best available international science in understanding patterns of Thalidomide embryopathy. The algorithm will yield a probability based result on a three-point scale of the likelihood that your injuries are the result of maternal ingestion of Thalidomide in the first trimester of pregnancy. It is not a definitive medical test, but a probability assessment.

 

The term “probable” is the highest point on a three-point scale of the algorithm which ranges from “unlikely” to “probable” that your injuries are the result of maternal ingestion of Thalidomide in the first trimester of pregnancy.

 

Individuals with a probability result suggesting one’s injuries were the result of Thalidomide will advance to Step 3.

 

Step 3: Medical-Legal Panel Review:

 

At this step, a multidisciplinary committee of medical and legal experts will carefully consider the totality of the information related to your application and any other evidence the committee considers relevant. This could include genetic test results and medical exams it may requisition, to formulate its recommendation to the Administrator that an individual is eligible for support under the CTSSP.

 

The CTSSP Application period will be open for a five year period beginning June 3, 2019 and ending June 3, 2024.

Need Help

Address

a